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The Suppressor of Cytokine Signaling (SOCS)-3
Determines Keratinocyte Proliferative and Migratory
Potential during Skin Repair
Andreas Linke1, Itamar Goren1, Michael R. Bo¨sl2, Josef Pfeilschifter1 and Stefan Frank1
Recently, the suppressor of cytokine signaling (SOCS)-3 has been shown to be expressed in disturbed wound
margin epithelia during diabetes-impaired wound healing in mice. To functionally connect a potential
contribution of SOCS-3 expression to the control of wound keratinocyte behavior in skin repair, we created a
transgenic mouse (tsgn-K5/SOCS3) overexpressing SOCS-3 in keratinocytes using the bovine keratin 5
promoter. Tsgn-K5/SOCS3 mice showed a constitutive expression of SOCS-3 in the basal layer of skin epidermis.
Keratinocytes of tsgn-K5/SOCS3 mice showed full inhibition of signal transducer and activator of transcription
(STAT)-3 phosphorylation. Tsgn-K5/SOCS3 keratinocytes also showed a strong inhibition of migratory and
proliferative potential in vitro. In addition, tsgn-K5/SOCS3 keratinocytes co-expressed the differentiation marker
loricrin in the basal layer of nonwounded skin in vivo. Upon wounding, wound tissues of tsgn-K5/SOCS3 mice
showed an impairment of wound closure characterized by strongly atrophied wound margin epithelia.
Atrophied epithelia of tsgn-K5/SOCS3 mice exhibited a marked reduction in proliferating cells and reduced
total keratinocyte numbers. In summary, this study suggests that the presence of SOCS-3 in keratinocytes
strongly disturbs epithelial repair of cutaneous wounds by interfering with keratinocyte proliferation and
migration.
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INTRODUCTION
It was the surgeon TD Pryce who first postulated a functional
connection between diabetes and foot ulceration in 1887. In
his article in The Lancet, he claimed, ‘‘Diabetes itself may
play an active part in the causation of perforating ulcers’’
(Pryce, 1887). Diabetic foot ulcers are skin lesions with a loss
of epithelium that may extend into the dermis and sometimes
involve bone and muscle (Reiber and Ledoux, 2002; Boulton,
2004). The loss of epithelial regeneration in particular may be
regarded as a critical point in disturbed repair, as the failure
to provide rapid epithelial coverage of the wound site might
be central in driving the healing disorder deeper into the
underlying tissue. Those diabetes-associated ulcerations
represent a serious clinical complication of wound healing
and indicate a significant mortality (Carrington et al., 2001;
Reiber and Ledoux, 2002). After amputation, diabetic ulcers
have a poor prognosis, with 3-year survival rates between 50
and 59% in developed countries (Apelqvist et al., 1993;
Faglia et al., 2001). Despite the urgent demand for new
treatment strategies, fundamental research unfortunately has
failed to identify the underlying molecular and cellular
mechanisms that might provide a basis for the development
of innovative therapies in order to treat those chronic
ulcerations (Jeffcoate and Harding, 2003).
To meet this demand, it appears reasonable to reevaluate
the functional interdependencies of the established processes
in normal healing, particularly with respect to their contribu-
tion to the development of a disturbed wound site.
Inflammation and wound re-epithelialization are central to
acute skin repair and determine the outcome of healing
(Martin, 1997; Singer and Clark, 1999). The use of a great
diversity of genetic mouse models resulted in the findings that
a tight control of inflammation directs the quality of tissue
repair and that excess inflammation is associated with
impaired wound healing (reviewed by Eming et al., 2007).
Wound healing studies, especially in obese/obese (ob/ob)
and diabetes/diabetes mouse models of obesity-associated
type 2 diabetes mellitus, have indicated an exacerbated
inflammatory response in chronic wound tissue (Wetzler
et al., 2000; Goren et al., 2003). Indeed, studies on ob/ob
mice showed that the resolution of prolonged wound
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inflammation by the depletion of macrophages allowed a
rapid and robust neo-epithelialization of disturbed wounds in
the presence of persisting hyperglycemic conditions (Goren
et al., 2007). In accordance with this finding, keratinocytes in
chronic wounds responded to increased cytokines with the
expression of the suppressor of cytokine signaling (SOCS)-3
(Goren et al., 2006), which is a negative regulator of the
JAK/signal transducer and activator of transcription (STAT)
signaling from cytokine receptors (Wormald and Hilton,
2004). It is interesting that this potential anti-inflammatory
function of SOCS-3 in keratinocytes appeared to potently
inhibit proliferation of the cells (Goren et al., 2006; Zhu et al.,
2008) and thus might amplify the deleterious effects of
inflammatory conditions in chronic wounds. To determine
the functional connection between the presence of SOCS-3
in keratinocytes and an augmented inflammation in diabetes-
impaired wounds with regard to keratinocyte movements, we
specifically overexpressed SOCS-3 in the epithelial compart-
ment of mice. Remarkably, experimental data from our study
show that the presence of SOCS-3 in wound keratinocytes
creates wound conditions in nondiabetic transgenic animals
that resemble those found in disturbed wounds of diabetic
ob/ob mice (Frank et al., 2000; Goren et al., 2003): reduced
keratinocyte proliferation in atrophied neo-epithelia (this
study) in the presence of an augmented inflammatory
response (Linke et al., 2009).
RESULTS
Constitutive overexpression of SOCS-3 in basal keratinocytes of
skin tissue in transgenic tsgn-K5/SOCS3 mice
To determine a potential functional connection between the
observed upregulation of SOCS-3 in wound keratinocytes
(Goren et al., 2006) and severely disturbed re-epithelializa-
tion in diabetes-impaired wounds of mice (Frank et al., 2000;
Goren et al., 2003), we first cloned the murine cDNA of the
SOCS-3 open reading frame (Starr et al., 1997) downstream
of the bovine keratin (K) 5 promoter (Figure 1a). The 5-kb
bovine K5 promoter fragment had been shown to specifically
drive the expression of transgenes in basal keratinocytes of
the epithelial skin compartment in diverse models of
engineered animals (Casatorres et al., 1994; Neufang et al.,
2001). Microinjection of constructs into oocytes of C57BL/6
and FVB/N mice led to founder animals, which were
analyzed for transgene integration by PCR and Southern
hybridization analyses of genomic DNA (Supplementary
Figure S1).
Analysis of transgene integration was followed by
determination of keratinocyte-specific expression of the
SOCS-3 transgene. Figure 1 illustrates SOCS-3 mRNA and
protein expression in the F2 generation of established
tsgn-K5/SOCS3 mouse lines in the C57BL/6 and FVB/N
genetic backgrounds. Analyses of individual tsgn-K5/SOCS3
mice proved that the bovine K5 promoter activity was
Kpnl
5 kb
ATG
0.7 kb 1.8 kb
pBSKS(+)poly-ASOCS-3bovine K5 promoterpBSKS(+)
BamHI
Pr
ob
e
L1
3
1 2
Non-tsgn
Pr
ob
e
Ep
id
er
m
is
D
er
m
is
D
er
m
is
D
er
m
is
D
er
m
is
D
er
m
is
Ep
id
er
m
is
Ep
id
er
m
is
Ep
id
er
m
is
Ep
id
er
m
is
po
s 
ct
rl
Ep
id
er
m
is
D
er
m
is
Ep
id
er
m
is
D
er
m
is
Ep
id
er
m
is
D
er
m
is
Non-tsgntsgn-K5/SOCS3 tsgn-K5/SOCS3
SOCS-3
SOCS-3
SOCS-3
β-Actin
33 kDa
L1
3
GAPDH
L13L12L8Non-tsgn Non-tsgn tsgn-K5/SOCS3
GAPDH PonS
SOCS-3
321321
33 kDa
L1
3
3 1 2 3
Sal l Cla l Kpnl L1
3
Pr
ob
e
Ba
ck
 s
ki
n
Ve
n
tra
l s
ki
n
H
ea
rt
Lu
ng
Sp
le
en
Ki
dn
ey
In
te
st
in
e
Br
a
in
M
us
cl
e
Li
ve
r
SOCS3
GAPDH
Figure 1. Generation and analysis of tsgn-K5/SOCS3mice. (a) Scheme of the recombinant DNA construct including the bovine K5 promoter, murine suppressor
of cytokine signaling-3 (SOCS-3) cDNA, and a 1.8-kb polyadenylation signal of the bovine keratin 5 gene. The 7.5-kb KpnI fragment was injected into oocytes.
(b) Representative RNase protection assay showing SOCS-3 mRNA expression in different tissues of an individual transgenic mouse (line L13). Hybridization
against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is shown as a loading control. (c) RNase protection assay (left panel) and immunoblot (right
panel) analyses for SOCS-3 expression in isolated skin tissue of individual nontransgenic (non-tsgn) and transgenic (tsgn-K5/SOCS3) littermates of transgenic
mice (line L13). (d) The dermis and epidermis were separated by incubation of tail skin in 2M NaBr for 30minutes at 37 1C. The dermis and epidermis of
transgenic lines L8, L12, and L13 (as indicated) were analyzed for SOCS-3 mRNA (left panel) and protein expression (right panel). b-Actin and GAPDH were
used to control for equal loading.
www.jidonline.org 877
A Linke et al.
SOCS-3 Expression in Keratinocytes
keratinocyte-specific and restricted the expression of SOCS-3
to the skin epithelium: In accordance with the reported
low levels of SOCS expression under steady-state conditions
(Alexander and Hilton, 2004), SOCS-3 mRNA was
almost absent in all tissues examined except skin tissue
(Figure 1b). Moreover, we found a robust expression of
SOCS-3 mRNA and protein (Figure 1c) in skin tissue isolated
from transgenic mice, which was absent in nontransgenic
littermates. Separation of epidermal and dermal compart-
ments of skin tissue isolated from tsgn-K5/SOCS3 mice
clearly showed the restricted appearance of SOCS-3 mRNA
and protein in the epidermis of different transgenic lines
(Figure 1d).
Finally, we investigated the in situ expression of SOCS-3
protein in the skin of tsgn-K5/SOCS3 mice using immuno-
histochemistry. We initially examined skin biopsies for
potential SOCS-3-driven changes in the normal skin archi-
tecture, as morphological changes in transgenic mice might
also modify wound healing. Tail-skin histology, via eosin-
stained sections, did not show any obvious changes in skin
morphology (Figure 2, upper panels). However, immuno-
logical staining for SOCS-3 indeed showed the presence of
the protein in the basal layer of the epidermis and the outer
root sheet of the hair follicles in tsgn-K5/SOCS3 mice
(Figure 2, lower panels).
Overexpression of SOCS-3 interferes with keratinocyte
proliferation, differentiation, and migration
Recently, we examined the potential functional role of SOCS-3
in keratinocytes (Goren et al., 2006). In this set of experiments,
we showed that stable overexpression of SOCS-3 protein in the
human HaCaT keratinocyte cell line (Boukamp et al., 1988) was
functionally related to a reduction in serum-stimulated prolif-
eration correlating with SOCS-3 expression levels (Supplemen-
tary Figure S2). Moreover, SOCS-3-related reduction of cellular
proliferation was associated with differentiation processes. We
found increased levels of the early keratinocyte differentiation
markers K1 and K10 (Schweizer and Winter, 1983) only in the
SOCS-3-overexpressing HaCaT lines, not in the mock-trans-
fected ones (Supplementary Figure S2).
In this study, we used the tsgn-K5/SOCS3 mouse model to
investigate this potential connection between SOCS-3 and
keratinocyte proliferation (Goren et al., 2006) in vitro and
during skin repair in vivo. To this end, we first isolated
primary keratinocytes from newborn transgenic mice, which
strongly expressed SOCS-3 in vitro (Figure 3a, left panel; right
panel: ctrl). SOCS-3 protein was functional, as basal and IL-6-
stimulated activation of the JAK/STAT signaling pathway
(Alexander and Hilton, 2004; Wormald and Hilton, 2004)
was completely abrogated in the presence of overexpressed
SOCS-3 protein (Figure 3a, right panel). Moreover, in
accordance with the reported interference of SOCS-3 with
human keratinocyte proliferation, we observed a visible
reduction in growth rates of cultured primary keratinocytes of
tsgn-K5/SOCS3 mice in contrast to cells isolated from
nontransgenic littermates in vitro. This observation is
supported by the finding that tsgn-K5/SOCS3 keratinocytes
showed a markedly impaired proliferation under diverse
conditions of stimulation as assessed by [3H]thymidine
incorporation (Figure 3c). Inhibition of proliferation was
again associated with an increased appearance of mRNA
encoding the keratinocyte differentiation marker K10 in
transgenic cells (Figure 3d). In line with this, we observed
an elevated percentage of morphologically altered keratino-
cytes within transgenic keratinocyte cultures that resembled a
phenotype of in vitro differentiating cells (Figure 3b).
Because migration of keratinocytes also represents a critical
event in re-epithelialization of skin wounds (Martin, 1997), we
assessed the role of SOCS-3 in this process. Therefore, we
cultured primary keratinocytes of nontransgenic and transgenic
animals and performed an in vitro wound assay (scratch assay).
To do so, we ‘‘injured’’ the subconfluent keratinocyte mono-
layer using a pipette tip and subsequently measured the number
of keratinocytes that migrated into the open space within
24hours after ‘‘injury’’. It became evident that nontransgenic
keratinocytes potently and efficiently populated the cell-free
spaces under conditions of nonsupplemented keratinocyte basal
medium (KBM), KBM in the presence of IL-6, or supplemented
keratinocyte growth medium (KGM). By contrast, tsgn-K5/
SOCS3 keratinocytes failed to migrate into the open space even
after 24hours (Figure 4a and b).
To strengthen our in vitro data on the role of SOCS-3 in the
regulation of keratinocyte proliferation and differentiation,
we analyzed the nonwounded skin tissue of tsgn-K5/SOCS3
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Figure 2. Localization of SOCS-3 protein in tsgn-K5/SOCS3 mouse skin.
Frozen sections of nonwounded tail skin isolated from nontransgenic
(non-tsgn) and transgenic (tsgn-K5/SOCS3) mice as indicated were stained
with hematoxylin (upper panels) or incubated with an antibody directed
against suppressor of cytokine signaling-3 (SOCS-3) protein (lower panels).
Immunopositive signals are highlighted by yellow arrows. d, dermis;
e, epidermis; h, hair follicle. Bars¼ 100mm (hematoxylin) or 50 mm
(SOCS-3 staining). Inset: higher magnification showing skin epithelium.
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mice for the presence and distribution of the proliferation
marker protein Ki67 (Gerdes et al., 1984) and the marker of
terminal keratinocyte differentiation loricrin (Mehrel et al.,
1990; Steven et al., 1990). In accordance with in vitro data
indicating elevated levels of the differentiation marker K10 in
transgenic cells, these analyses showed the presence of
loricrin in the basal layer of skin epithelium and reduced
numbers of Ki67-positive basal keratinocytes (Supplementary
Figure S3) in tail skin of tsgn-K5/SOCS3 mice.
Tsgn-K5/SOCS3 mice show a markedly impaired skin repair
associated with disturbed re-epithelialization
Next, we aimed to transfer our in vitro findings on the
inhibitory role of SOCS-3 on keratinocyte proliferation to the
study of the dynamic process of tissue regeneration. This was
important, as we have previously reported the prolonged
presence of keratinocyte-expressed SOCS-3 protein in
diabetes-impaired wounds (Goren et al., 2006). Tsgn-K5/
SOCS3mice were characterized by a marked delay in wound
closure upon excisional wounding (Figure 5a) paralleled by a
strong expression of SOCS-3 at wounded sites throughout the
entire period of acute repair (Figure 5b, upper panel). In
transgenic animals, we observed particularly high SOCS-3
mRNA expression levels at early stages of repair (days 3 and 5
after wounding). Here, we analyzed skin- and wound-derived
K5 mRNA levels to reflect the K5 promoter–driven SOCS-3
expression in the respective tissue in transgenic mice. This
analysis revealed a K5 mRNA expression, which appeared
independent of different stages of the developing wound
epithelium (Figure 5b, lower panel). Moreover, this observa-
tion suggested an epithelium-driven, constitutive, and thus
basic expression of SOCS-3 mRNA within the observed
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Figure 3. SOCS-3 interferes with proliferation of primary mouse keratinocytes. (a) RNase protection assay showing suppressor of cytokine signaling-3
(SOCS-3) mRNA expression in cultured primary keratinocytes of nontransgenic (non-tsgn) and transgenic (tsgn-K5/SOCS3) mice (left panel). The nontransgenic
(ntg) and transgenic (tg) cells were stimulated with increasing concentrations of IL-6 as indicated and analyzed for phosphorylated STAT-3 by immunoblot
(right panel). Total signal transducer and activator of transcription (STAT)-3 and SOCS-3 protein are shown as controls. (b) Photograph of isolated nontransgenic
(non-tsgn) and transgenic (tsgn-K5/SOCS3) keratinocytes at 36 hours after reaching confluency. Bars¼ 200mm. (c) Keratinocyte growth medium (KGM)-,
IL-6-, and transforming growth factor (TGF)-a-supplemented keratinocyte basal medium (KBM)-stimulated proliferation (percentage of KGM-treated non-tsgn
cells) of nontransgenic (non-tsgn) and transgenic (tsgn-K5/SOCS3) keratinocytes after 24 hours. **Po0.01. Data represent means±SEM obtained from four
independent cell culture experiments (n¼4). (d) PCR analysis for keratin 10 expression in exponentially growing nontransgenic (ntg) and transgenic
(tg) keratinocytes. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) amplicons are shown for equal loading.
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expression pattern in transgenic animals, which was added to
the physiological induction of SOCS-3 in the epithelium and
granulation tissue in nontransgenic animals (Goren et al.,
2006). The observed delay in wound closure in tsgn-K5/
SOCS3 mice appeared to be functionally caused by epithelial
impairments during acute healing. Although wounds in
nontransgenic mice were completely re-epithelialized at
day 7 after wounding, wounds of tsgn-K5/SOCS3 mice failed
to form a complete neo-epidermis at this particular stage of
repair (Figure 5c and d).
This finding is highlighted again in Figure 6. Upon injury,
tsgn-K5/SOCS3 mice failed to generate large, multicel-
lular wound margin epithelia that integrated deep into the
underlying tissue, but showed flat epithelia consisting of
reduced keratinocyte numbers (Figure 6a and c). Further
analysis of wound tissue sections of the animals indicated
a markedly reduced mitogenicity of wound keratinocytes
as assessed by staining of the proliferation marker protein
Ki67 and determination of BrdU incorporation into dividing
cells (Figure 6b and d). Remarkably, impaired wound mar-
gin epithelia in tsgn-K5/SOCS3 mice were characterized
by an expression of the keratinocyte differentiation marker
loricrin in almost all cells of the epithelial wound margin,
whereas wound margin epithelia in nontransgenic
animals showed expression of loricrin in the upper and distal
parts, but not in the leading edge of the epithelial tongue
(Figure 7).
DISCUSSION
Chronic wounds represent diverse conditions of cutaneous
lesions that fail to undergo the coordinated progress of
differential cellular movements necessary for normal tissue
repair: the inflammatory response, the proliferation of resident
cells in order to form a granulation tissue and neoepithelia, the
deposition of new matrix, controlled apoptosis, and matrix
modifications during remodeling (Martin, 1997; Singer and
Clark, 1999). Nonhealing chronic wound conditions have
been intensively investigated during the past two decades.
However, clinical studies on growth factors have failed to
show beneficial effects, with platelet-derived growth factor-BB
as the only exception (Smiell et al., 1999). The failure of
therapeutically applied recombinant growth factors to improve
impaired wound repair might also result from potential
phenotypical changes in resident wound cells in direct
response to a chronically inflamed wound milieu (Pierce,
2001). Here, augmented inflammation must be discussed as
one potential cause of changes in the responsiveness of
resident cells in chronic wounds to external signals. In line
with this argument, fibroblasts isolated from chronic diabetic
ulcers have been shown to be less responsive to epidermal
growth factor (EGF), insulin-like growth factor-1, basic
fibroblast growth factor, or platelet-derived growth factor-BB
with respect to cell proliferation (Loot et al., 2002). The loss in
sensitivity is most likely a consequence of the loss of receptors,
as transforming growth factor (TGF)-b receptor type 2
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expression has been shown to be decreased and paralleled by
impaired intracellular activation of Smad2, Smad3, and
mitogen-activated protein kinase (Kim et al., 2003).
These findings imply that the persistence of inflammatory
cytokines in chronic wounds changes the responsive pheno-
type of pivotal wound cell types. When the inflammatory
response is corrected in ob/ob mice either by leptin
supplementation (Goren et al., 2003) or by inactivation of
wound macrophages (Goren et al., 2007), impaired wounds
rapidly change into healing tissue. One consequence must be
considered as a possible explanation for the mentioned
therapeutic failure of recombinant factors to improve
chronic wound conditions: wound target cells cannot
respond even in the presence of an adequate stimulus, as
they have changed intracellular signaling capabilities in
response to inflammation.
This notion is supported by the finding that we observed
the appearance of SOCS-3 in atrophied wound margin
epithelia in extensively inflamed and nonhealing wounds of
diabetic ob/ob mice (Goren et al., 2006). Here, SOCS-3
might serve as a candidate protein that can shed new light on
the interactive relation between inflammation and cellular
changes in wound keratinocytes. Most likely, SOCS-3 is
increased in keratinocytes by persisting cytokines during
repair, as all known members of the SOCS family of proteins
(SOCS-1 to -7 and cytokine-inducible SH2-domain-contain-
ing protein) are induced by inflammatory cytokines. SOCS
proteins mediate a negative feedback response to cytokine
stimulation, as they attenuate signal transduction by inhibi-
tion of JAK and STAT actions and by targeting signaling
proteins for proteasomal degradation (Alexander and Hilton,
2004; Wormald and Hilton, 2004). However, once induced
in keratinocytes in response to wound cytokines (Goren
et al., 2006), SOCS-3 actions might become independent,
rendering wound keratinocytes deleteriously independent of
external control.
To investigate this possibility and the potential conse-
quences for tissue repair, we generated transgenic tsgn-K5/
SOCS3 mice, which were characterized by a keratinocyte-
specific expression of SOCS-3. Interestingly, transgenic
animals showed a markedly disturbed wound closure, which
was due to impairments in keratinocyte proliferation and
migration, both being essential processes for skin repair
(Martin, 1997; Singer and Clark, 1999). SOCS-3 expression
appears to be a common feature of ‘‘activated’’ keratinocytes,
as SOCS-3 has also been reported to be expressed in psoriatic
keratinocytes, in which the protein downregulated keratino-
cyte response to IFN-g (Friedrich et al., 2003). However, the
primary function of SOCS-3 in keratinocyte biology might be
its inhibitory effect on the activation of the JAK-2/STAT-3
signaling pathway (Yamasaki et al., 2003; Tokumaru et al.,
2005b). It is reasonable to suggest that the main function of
cytokine-induced SOCS-3 comprises its interference with
STAT-3 activation, which has been shown to be of great
importance in the control of keratinocyte proliferation
and migration: constitutively activated STAT-3 mediates
keratinocyte hyperproliferation (Sano et al., 2005) and also
transduces signals required for keratinocyte migration
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Figure 5. Keratinocyte-specific overexpression of suppressor of cytokine
signaling-3 (SOCS-3) impairs wound healing. (a) In situ wound phenotypes
of acute 5-day wounds in nontransgenic (non-tsgn) and transgenic
(tsgn-K5/SOCS3) mice. The initial wounding situation (d0) is given in the
center. (b) RNase protection assay showing SOCS-3 and keratin 5 mRNA
expression within the identical set of wound RNA from nontransgenic (non-
tsgn) and transgenic (tsgn-K5/SOCS3) mice as indicated. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is shown as a loading control. (c)
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from nontransgenic (non-tsgn) and transgenic (tsgn-K5/SOCS3) mice.
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or 1mm (d).
www.jidonline.org 881
A Linke et al.
SOCS-3 Expression in Keratinocytes
(Sano et al., 1999). These findings strongly support the
proliferative and migratory defects observed in SOCS-3-over-
expressing keratinocytes, which showed a complete abrogation
of STAT-3 activation (this study). Furthermore, the keratino-
cyte-specific conditional ablation of SOCS-3 in transgenic
mice resulted in an aberrant STAT-3 activation associated
with keratinocyte hyperproliferation (Zhu et al., 2008).
In addition, SOCS-3 has also been shown to interfere with
downstream signaling from the EGF receptor (EGFR). This is
of importance within our set of experiments, as EGF and
heparin-binding EGF stimulate keratinocyte proliferation and
migration through activation of the EGFR and thus drive
wound closure (Barrandon and Green, 1987; Martin, 1997).
In particular, non-EGFR ligands promote a transactivation of
the EGFR through release of membrane-bound heparin-
binding EGF (Asakura et al., 2002). Here, it is reasonable to
suggest that SOCS-3 expression in keratinocytes might also
interfere with induced keratinocyte migration by EGFR
transactivation, as this phenomenon is lost upon SOCS-3
overexpression in the cells (Tokumaru et al., 2005a). SOCS-3
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Figure 6. Atrophied wound margin epithelia in wound tissue of tsgn-K5/SOCS3 mice. Frozen sections of 5-day wounds isolated from nontransgenic (non-tsgn)
and transgenic (tsgn-K5/SOCS3) mice were stained with hematoxylin (a) or analyzed for the incorporation of BrdU and for the presence of the proliferation
marker protein Ki67 (b) as indicated. The epithelial boundaries are highlighted by a red dotted line in panel a. Immunopositive signals are indicated by yellow
arrows in panel b. gt, granulation tissue; he, hyperproliferative epithelium. Bars¼ 200 mm. Total keratinocyte numbers (c) or BrdU-positive keratinocytes (d) in
5-day neo-epithelia of non-transgenic (non-tsgn) and transgenic (tsgn- K5/SOCS-3) mice. **Po0.01 as compared with nontransgenic mice. Data represent
means±SEM obtained from eight wounds (n¼ 8) isolated from four animals.
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appears as an interesting internal signaling protein located at
an interface where an augmented wound inflammation
coincides with resident cells at wounded sites. Therefore,
SOCS-3 might drive cellular changes in the translation of an
inflammatory wound milieu into deleterious cell responses
that contribute to an impairment of the healing process.
Importantly, the tsgn-K5/SOCS3 mice contribute to our
understanding of the development of diabetes-impaired
wounds. SOCS-3 overexpression obviously represents a
single prerequisite for the creation of disturbed wound
conditions that resemble a diabetes-impaired wound mor-
phology in metabolically healthy animals. SOCS-3 expres-
sion led to reduced wound margin epithelia owing to
interference with STAT-3 activation as discussed above.
However, an additional study in tsgn-K5/SOCS3 animals
showed that impaired epithelial motion also resulted in an
exacerbated inflammatory response in wound tissue (Linke
et al., 2009). Despite the notion that excess inflammation is
regarded as provoking keratinocyte disturbances and sus-
tained chronic ulceration (Pierce, 2001; Eming et al., 2007),
our model now suggests an inversion of the causal linkage
between inflammation and associated tissue defects. It
became evident that small changes in the intracellular
signaling machinery of keratinoytes—initially caused by the
underlying diabetic disease (Goren et al., 2006) and
experimentally mimicked by a transgenic overexpression of
SOCS-3 (this study)—might turn out to be as destructive as
excessive wound inflammation, and also might be much
more resistant to therapeutic interventions as a consequence.
MATERIALS AND METHODS
Generation of transgenic mice (tsgn-K5/SOCS3)
The cDNA of the murine SOCS-3 open reading frame (Starr et al.,
1997) was generated by PCR using the following DNA oligonucleo-
tides: 50-ATAGACTAGTCGACCTCCGTGCGCCATGGTCACCCACA
GCAAGTTTCCC-30 and 50-GAGCGCCGATCGATTTAAAGTGGAG
CATCATACTGATCCAGGAAC-30. It was subsequently inserted into
the bovine cytokeratin III minilocus expression vector (Blessing et al.,
1993; Amendt et al. 1998) downstream of the K5 promoter and
upstream of the splice and polyadenylation signals derived from the
bovine K5 gene, using SalI and ClaI restriction sites (refer to Figure 1a).
The complete construct was verified by sequencing. The 7.5-kb
K5/SOCS-3 expression cassette (isolated as a KpnI fragment (Figure 1a))
was microinjected into the pronuclei of fertilized C57BL/6 and FVB/N
oocytes. One-cell embryos were subsequently transferred into
pseudopregnant fosters of outbred strain CD1. Four transgenic mouse
lines were established (L3, L8, L12, and L13). All displayed a site-
directed transgene expression and disturbances in skin repair upon
wounding. Further experiments were performed using the line L13.
Analysis of transgenic mice
Founder animals were analyzed for transgene integration by South-
ern blot analysis of BamHI-digested genomic tail DNA and a DNA
probe complementary to the 0.7-kb SOCS-3 cDNA (refer to Figure
1a). In addition, PCR analyses were carried out on genomic tail DNA
using primers specific for the 30-end of the bovine K5 promoter
(50-CACTTAATCATTCACAGCTCG-30) and for the 50-end of murine
SOCS-3 cDNA (50-CACCGCGCTCCAGTAGAATCC-30), resulting in
a 319-bp amplicon. Sex-matched nontransgenic littermates were
used as controls.
Wounding of mice
Wounding of mice was performed as described previously (Frank
et al., 1999; Stallmeyer et al., 1999). Briefly, mice were anesthetized
with a single intraperitoneal injection of ketamine (80mg per kg
body weight)/xylazine (10mg per kg body weight). The hair on the
back of each mouse was shaved, and the back was subsequently
wiped with 70% ethanol. Six full-thickness wounds (5mm in
diameter, 3–4mm apart) were made on the back of each mouse by
excising the skin and the underlying panniculus carnosus. The
wounds were allowed to form a scab. Skin biopsy specimens were
obtained from the animals at 1, 3, 5, 7, and 13 days after injury. At
each time point, an area that included the scab, the complete
epithelial and dermal compartments of the wound margins, the
granulation tissue, and parts of the adjacent muscle and subcuta-
neous fat tissue was excised from each individual wound. As a
control, a similar amount of skin was taken from the backs of
nonwounded mice. If not indicated otherwise, wounds (n¼ 12)
isolated from animals (n¼ 4) were used for RNA analysis. For
immunoblot analysis, wounds (n¼ 8) from individual mice (n¼ 4)
were used. All animal experiments were performed according to the
guidelines and approval of the local animal ethics animal review
board (Regierungspra¨sidium Darmstadt, Hessen, Germany).
In vivo BrdU labeling of proliferating cells
Mice were wounded as described above. At day 5 of injury, mice
received a peritoneal injection of 1.6mg BrdU (in 0.5ml phosphate-
buffered saline) 3 hours before animals were killed.
RNA isolation and RNase protection analysis
RNA isolation from wounds and cultured keratinocytes and
RNase protection assays were carried out as described previously
(Chomczynski and Sacchi, 1987; Frank et al., 1999). All samples
were quantified using PhosphorImager PSL counts per 15 mg of
total wound RNA. A GAPDH hybridization is shown as a loading
control. A total of 1,000 c.p.m. of the hybridization probe was
used as a size marker. Hybridization against tRNA was used to show
the specificity of the probe. The murine cDNA probes were cloned
using reverse transcriptase-PCR. The probes corresponded to
nucleotides (nt) 383–660 (for SOCS-3, GenBank accession number
Non-tsgn
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Figure 7. Differential distribution of loricrin expression. (a) Frozen sections
of 5-day wounds isolated from nontransgenic (non-tsgn) and transgenic
(tsgn-K5/SOCS3) mice were analyzed for the presence of the differentiation
marker protein loricrin. The epithelial boundaries are highlighted by a red
dotted line. Immunopositive signals are indicated by yellow arrows.
Bar¼200 mm.
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U88328) and nt 163–317 (for GAPDH, NM002046) of the published
sequences.
Immunohistochemistry
Wounding of mice was performed as described above. Animals were
killed at days 5 and 7 after injury. Biopsies of nonwounded skin and
skin wounds were isolated from the back and subsequently embedded
in Tissue Freezing Medium (Tissue Tek, Sakura, Zoeterwonde, The
Netherlands). Six-micrometer sections were counterstained with
hematoxylin to document overall wound morphology. Sections were
subsequently incubated overnight at 4 1C with antisera raised against
SOCS-3 (Santa Cruz Biotechnology, Heidelberg, Germany), loricrin
(Covance, Berkeley, CA), BrdU (AbD Serotec, Hamburg, Germany),
or Ki67 (Dianova, Hamburg, Germany). Primary antibodies were
detected using a biotinylated secondary antibody. The slides were
subsequently stained with the avidin–biotin–peroxidase complex
system (Santa Cruz Biotechnology) using 3,30-diaminobenzidine
tetrahydrochloride as a chromogenic substrate. Finally, sections were
counterstained with hematoxylin and mounted.
Determination of wound keratinocyte numbers
Low-magnification ( 40) photographs of sections were analyzed for
total keratinocyte cell numbers within the neo-epithelia of non-
transgenic and tsgn-K5/SOCS3 mice by counting hematoxylin-
stained keratinocyte nuclei.
Reverse transcriptase–PCR
Total cellular RNA from primary keratinocytes was reverse-
transcribed using random hexamer primers (Roche, Mannheim,
Germany) and SuperScript reverse transcriptase. PCR for murine K10
was carried out on total cDNA using 50-CAGCTACGGCGGCG
GAAGC-30 and 50-GGTGTCACCTCCTCAATAATCG-30 and 30
cycles of amplification.
Preparation of protein lysates and western blot analysis
Skin tissue biopsies and cultured keratinocytes were homogenized in
lysis buffer (1% Triton X-100, 20mM Tris/HCl (pH 8.0), 137mM NaCl,
10% glycerol, 1mM dithiothreitol, 10mM NaF, 2mM Na3VaO4, 5mM
EDTA, 1mM phenylmethylsulfonyl fluoride, 5 ngml1 aprotinin, and
5ngml1 leupeptin). Extracts were cleared by centrifugation. Protein
concentrations were determined using the BCA Protein Assay Kit
(Pierce, Rockford, IL). Fifty micrograms of total protein from skin or
cellular lysates was separated using SDS gel electrophoresis. After
transfer to a nitrocellulose membrane, specific proteins were detected
using antisera raised against SOCS-3 (Santa Cruz Biotechnology), total
STAT-3 and phosphorylated STAT-3 (New England Biolabs, Frankfurt,
Germany), and b-actin (Sigma, Taufkirchen, Germany). A secondary
antibody coupled to horseradish peroxidase and the enhanced
chemiluminescence detection system was used to visualize the
proteins. Phenylmethylsulfonyl fluoride, dithiothreitol, aprotinin,
NaF, and Na3VaO4 were purchased from Sigma. Leupeptin and
okadaic acid were purchased from BioTrend (Cologne, Germany).
The enhanced chemiluminescence detection system was obtained
from Amersham (Freiburg, Germany).
Culturing of keratinocytes
HaCaT cells (Boukamp et al., 1988) were grown in DMEM with 10%
fetal bovine serum, 2mmol l1 L-glutamine, and 1% penicillin/
streptomycin (GIBCO/Life Technologies, Karlsruhe, Germany). Primary
keratinocytes of nontransgenic and tsgn-K5/SOCS3 mice were isolated
from the skin of newborn mice (1–3 days) by overnight incubation using
dispase (2.4Uml1, 4 1C). After dispase digestion, the epidermal layer
was separated from the dermis and subsequently treated with trypsin
(0.04%)/EDTA (0.03%) for an additional 7minutes to disaggregate
cells. After filtration (70mm; Falcon, Becton Dickinson Labware,
Heidelberg, Germany), keratinocytes were collected by centrifugation
(210g, 2minutes) and plated into fibronectin (for migration assays)- or
collagen IV (for proliferation assays)-coated dishes using the following
media: nonsupplemented KBM (PromoCell, Heidelberg, Germany),
KGM supplemented according to the supplier (PromoCell). Generation
of SOCS-3-overexpressing cell lines was described by Goren et al.
(2006). Confluent keratinocytes were stimulated with fetal calf serum
(10% v/v), IL-6 (10ngml1), or TGF-a (10ngml1). Fetal calf serum
was purchased from Gibco/Invitrogen (Karlsruhe, Germany), IL-6 was
from Peprotech (Frankfurt, Germany), TGF-a was from Roche, and
fibronectin and collagen IV were from Sigma.
Proliferation assay
A total of 4.0 107 primary keratinocytes per well, isolated from
tsgn-K5/SOCS3 mice or nontransgenic littermates, were seeded into
24-well plates. After reaching 50% confluence, cells were starved for
24 hours with KBM (PromoCell). Proliferation of cells was assessed
using 1 mCiml1 of [3H]methyl-thymidine in KGM or KBM
(PromoCell) in the presence or absence of IL-6 (10 ngml1) or
TGF-a (10 ngml1) for 24 hours. After 24 hours, cells were washed
twice with phosphate-buffered saline and incubated in 5%
trichloroacetic acid at 4 1C for 30minutes, and the DNA was
solubilized in 0.5 M NaOH for 30minutes at 37 1C. Finally,
[3H]thymidine incorporation was determined.
In vitro keratinocyte migration assay
A total of 4.0 106 freshly isolated keratinocytes were plated in dishes
precoated with fibronectin until they reached subconfluence. Cells
were then starved in KBM (PromoCell) and treated with mitomycin C
(10mgml1) (Sigma) for 2hours to inhibit cellular proliferation. A cell-
free area was introduced into the monolayer by scraping the dish with
a yellow pipette tip (Sano et al., 1999). Cell migration into the cell-free
area was assessed in KGM or KBM in the presence or absence of IL-6
(10ngml1). Photographs were taken using a phase-contrast micro-
scope (Axioskop 2, Carl Zeiss Optik, Jena, Germany).
Statistical analysis
Data are shown as means±SD or±SEM as indicated. Data analysis
was carried out using the unpaired Student’s t-test with raw data.
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